Clinical features
| . | No. . | % . |
|---|---|---|
| Age (median 9 y, range 0-19 y) | ||
| Less than 15 y | 289 | 81.6 |
| More than 15 y | 65 | 18.4 |
| Diagnostic WBC count (× 109/L) | ||
| Less than 1 | 5 | 1.4 |
| 1 to 50 | 214 | 60.5 |
| 51 to 100 | 31 | 8.7 |
| More than 100 | 60 | 16.9 |
| NA | 44 | 12.4 |
| Immunophenotype | ||
| B-cell precursor CD10+ | 174 | 47.9 |
| B-cell precursor CD10− | 25 | 6.9 |
| B cell mature | 29 | 8.9 |
| T cell | 37 | 10.2 |
| Other/NA | 98 | 27.0 |
| Cytogenetics | ||
| Normal | 236 | 65.0 |
| Hyperdiploid or hypodiploid | 35 | 9.6 |
| t(9;22) or t(8;14) or t(14;18) | 22 | 6.1 |
| Other | 70 | 19.3 |
| Extramedullary disease | ||
| Present | 52 | 14.3 |
| Absent | 294 | 83.0 |
| NA | 17 | 4.7 |
| CR1 duration, mo | ||
| Less than 1 to 5 | 45 | 12.4 |
| 6 to 12 | 32 | 8.8 |
| 13 to 24 | 81 | 22.3 |
| 25 to 36 | 80 | 22.0 |
| More than 36 | 76 | 22.9 |
| NA | 49 | 13.5 |
| Donor/patient CMV status | ||
| Donor negative/patient negative | 154 | 42.4 |
| Donor negative/patient positive | 73 | 20.1 |
| Donor positive/patient negative | 77 | 21.2 |
| Donor positive/patient positive | 51 | 14.0 |
| NA | 8 | 2.2 |
| Conditioning | ||
| CPM + TBI ± other | 310 | 85.4 |
| Other + TBI | 21 | 5.8 |
| Chemotherapy only | 32 | 8.8 |
| GVH disease prophylaxis | ||
| CSA or FK506 + MTX ± CS ± ALS | 212 | 58.4 |
| CSA or FK506 ± CS ± ALS | 117 | 32.2 |
| CSA and/or ALS | 23 | 6.3 |
| MTX | 1 | 0.3 |
| NA | 10 | 2.8 |
| . | No. . | % . |
|---|---|---|
| Age (median 9 y, range 0-19 y) | ||
| Less than 15 y | 289 | 81.6 |
| More than 15 y | 65 | 18.4 |
| Diagnostic WBC count (× 109/L) | ||
| Less than 1 | 5 | 1.4 |
| 1 to 50 | 214 | 60.5 |
| 51 to 100 | 31 | 8.7 |
| More than 100 | 60 | 16.9 |
| NA | 44 | 12.4 |
| Immunophenotype | ||
| B-cell precursor CD10+ | 174 | 47.9 |
| B-cell precursor CD10− | 25 | 6.9 |
| B cell mature | 29 | 8.9 |
| T cell | 37 | 10.2 |
| Other/NA | 98 | 27.0 |
| Cytogenetics | ||
| Normal | 236 | 65.0 |
| Hyperdiploid or hypodiploid | 35 | 9.6 |
| t(9;22) or t(8;14) or t(14;18) | 22 | 6.1 |
| Other | 70 | 19.3 |
| Extramedullary disease | ||
| Present | 52 | 14.3 |
| Absent | 294 | 83.0 |
| NA | 17 | 4.7 |
| CR1 duration, mo | ||
| Less than 1 to 5 | 45 | 12.4 |
| 6 to 12 | 32 | 8.8 |
| 13 to 24 | 81 | 22.3 |
| 25 to 36 | 80 | 22.0 |
| More than 36 | 76 | 22.9 |
| NA | 49 | 13.5 |
| Donor/patient CMV status | ||
| Donor negative/patient negative | 154 | 42.4 |
| Donor negative/patient positive | 73 | 20.1 |
| Donor positive/patient negative | 77 | 21.2 |
| Donor positive/patient positive | 51 | 14.0 |
| NA | 8 | 2.2 |
| Conditioning | ||
| CPM + TBI ± other | 310 | 85.4 |
| Other + TBI | 21 | 5.8 |
| Chemotherapy only | 32 | 8.8 |
| GVH disease prophylaxis | ||
| CSA or FK506 + MTX ± CS ± ALS | 212 | 58.4 |
| CSA or FK506 ± CS ± ALS | 117 | 32.2 |
| CSA and/or ALS | 23 | 6.3 |
| MTX | 1 | 0.3 |
| NA | 10 | 2.8 |
NA indicates not available; CPM, cyclophosphamide; TBI, total body irradiation; CSA, cyclosporine; MTX, methotrexate; CS, corticosteroids; and ALS, antilymphocyte serum.